Navigation Links
Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
Date:2/27/2008

SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference on Tuesday, March 4, 2008 at 4:30 p.m. EST (1:30 p.m. PST). The conference is being held at the W Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

Additionally, Dr. Worland will participate as a panel member in a discussion of the role of non-nucleoside and nucleoside polymerase inhibitors in the future of HCV therapy at the conference on Wednesday, March 5 at 9:15 a.m.

The corporate presentation on Tuesday, March 4 will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 18, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press releas
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Yuma Regional Cancer Center ... therapies brings comprehensive cancer care to Yuma, Arizona. ... Cancer Center has officially opened. A Mayo Clinic ... services such as open, semi-private and private infusion ... Society Resource Center, hematology, rehabilitation center, a pain ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
(Date:7/30/2014)... CT (PRWEB) July 30, 2014 Connecticut ... development organization based in East Hartford, Conn., was awarded ... Phase II of a project that will determine the ... in rural north-central Connecticut. USDA Rural Development provided $53,000 ... program for the second phase of the feasibility study ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 LayerBio, ... announces completion of its first round of seed financing ... will enable preliminary efforts to develop a novel sustained-release ... support of our investors and their commitment to this ... of LayerBio. "Ophthalmology is one of many areas in ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Inc., a privately held molecular diagnostics company developing innovative ... announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. ... Metamark with over 20 years of experience in cancer ... Dr. Blume-Jensen was department head at EMD Serono, Inc. ...
... 16 Cord Blood America, Inc . ( ... the umbilical cord blood stem cell preservation company ... stem cells, a biological insurance policy, to families nationwide ... and CEO, was interviewed by analyst Francis Gaskins on ...
... LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... Healthcare Conference on Tuesday, September 21st at 12:30 PM ET ... audio broadcast over the Internet available at http://investor.sigmaaldrich.com/ . ... About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, 'Afford-A-Cord,' and Profitability 2
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... how to create colors, nature had already perfected the ... different hues, for example. Now scientists are tapping into ... to make colored plastics. Their paper on using structure ... rather than dyes, to produce color appears in the ... Mortensen, Anders Kristensen and colleagues point out that currently, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Medicine have discovered a technique that directly converts skin ... patients with multiple sclerosis, cerebral palsy and other so-called ... in the journal Nature Biotechnology . This ... which provide a vital sheath of insulation that protects ...
... 14, 2013)Stenting reopens completely blocked bowel arteries, preventing ... causes individuals severe pain and leads to excessive ... Society of Interventional Radiology,s 38th Annual Scientific Meeting ... mesenteric arteries saves lives," said Daniel A. Leung, ...
... mechanism that causes a slime to form, making bacteria ... under threat, some bacteria can shield themselves in a ... made up of communities of bacteria held together to ... and sinusitis; in healthcare, biofilms can lead to life ...
Cached Biology News:Ordinary skin cells morphed into functional brain cells 2Stenting blocked bowel arteries saves lives 2Secrets of bacterial slime revealed 2
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Biology Products: